Cited by 384HIV-related health complications and treatmentsLipoproteins and Cardiovascular HealthHIV/AIDS Research and Interventions

Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

Open access
Friis-Møller, Nina, Thiébaut, Rodolphe, Reiss, Peter, Weber, Rainer, D'Arminio Monforte, Antonella, De Wit, Stephane, El-Sadr, Wafaa, Fontas, Eric +7 more·2010·European Journal of Cardiovascular Prevention & Rehabilitation

Abstract

AIMS: HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients. METHODS AND RESULTS: Prospective multinational cohort study. The data set included 22,625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score. The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score. CONCLUSION: Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/hjr.0b013e328336a150

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Friis-Møller, N., Thiébaut, R., Reiss, P., Weber, R., D'Arminio Monforte, A., De Wit, S., El-Sadr, W., Fontas, E., Worm, S., Kirk, O., Phillips, A., Sabin, C. A., Lundgren, J. D., Law, M. G., & DAD study group
Affiliations
  • Copenhagen HIV Programme (CHIP), University of Copenhagen/Faculty of Health Science, Copenhagen, Denmark
  • Inserm (FR)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • University Hospital Zurich (CH)
  • ICONA, Hospital San Paolo, University of Milan, Italy
  • Saint-Pierre Cohort, CHU Saint-Pierre Hospital, Brussels, Belgium
  • Columbia University Irving Medical Center (US)
  • Nice Cohort, CHU Nice Hopital de l'Archet, Nice, France
  • University of Copenhagen (DK)
  • The Royal Free Hospital (GB)
  • AHOD, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia
Venue
European Journal of Cardiovascular Prevention & Rehabilitation
Published
2010-10
Volume
17
Issue
5
Pages
491-501
ISSN
1741-8267 (ISSN-L)
OpenAlex
W2160970334
Cited by
384
References
43
Citations by year
2026: 6 · 2025: 11 · 2024: 13 · 2023: 12 · 2022: 16 · 2021: 28 · 2020: 23 · 2019: 25 · 2018: 16 · 2017: 38 · 2016: 36 · 2015: 43 · 2014: 24 · 2013: 33 · 2012: 34
FWCI
28.09
Type
journal article
Language
en
Open access
Locations
  • European Journal of Cardiovascular Prevention & Rehabilitation (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Murdoch University Research Portal (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • National Science Foundation
  • Bristol-Myers Squibb
  • Pfizer
  • GlaxoSmithKline
  • Gilead Sciences
  • European Commission (BIOMED2, CT94-1637, CT97-2713, QLK2-2000-00773)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (U01AI046362, U01AI042170, U01AI069907)
  • Cilag
Topics
  • Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords
cardiovascular risk prediction, HIV infection, antiretroviral therapy, highly active antiretroviral therapy, metabolic complications, myocardial infarction, coronary artery disease, indinavir, lopinavir/ritonavir, abacavir, Framingham risk score, cardiovascular risk factors
MeSH terms
Adult, Argentina, Australia, Coronary Disease, Drug Therapy, Combination, Europe, Female, Humans, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Risk Factors, Time Factors, Reproducibility of Results, Models, Statistical, HIV Infections, Treatment Outcome, Risk Assessment, Anti-HIV Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review